File downloaded on 2026-11-05
Source URL: https://medicines.health.europa.eu/veterinary/en/600000082965

Wellplus Flavoured Tablets

Authorised

- Praziquantel
- Pyrantel embonate
- Febantel

Product identification

Medicine name:
Wellplus Flavoured Tablets

Active substance:
Praziquantel

Pyrantel embonate

Febantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Praziquantel
50.00 milligram(s) / 1.00 Tablet

Pyrantel embonate

144.00 milligram(s) / 1.00 Tablet

Febantel
150.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP52AA30

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Available in:
Greece

Package description:
box containing 2 tablets (1 blister)
box containing 10 tablets (1 blister)
box containing 20 tablets (2 blisters)
box containing 50 tablets (5 blisters)
box containing 100 tablets (10 blisters)
box containing 300 tablets (30 blisters)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Divasa Farmavic S.A.

Marketing authorisation date:
18/01/2015

Manufacturing sites for batch release:
Divasa Farmavic S.A.

Responsible authority:
National Organization For Medicines

Authorisation number:
43841/18/24-01-2019/K-0201301

Date of authorisation status change:
23/01/2019

Reference member state:
Spain

Procedure number:
ES/V/0163/001

Concerned member states:
Belgium Bulgaria Germany Greece Ireland Netherlands Poland Portugal Romania Slovakia United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Package Leaflet

Labelling

eu-PUAR-wellplus-flavoured-tablets-en.pdf